Fab fragment anti-VEGF-A; first intravitreal anti-VEGF for wet AMD. 대표 임상 효능: ORR 7.3% (ClinicalTrials.gov NCT00486018).
VEGF-A
Wet AMD, DME, RVO, myopic CNV
Global
Approved
bispecific antibodies like faricimab that simultaneously target VEGF a
viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory
Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1
targeting angiopoietin-like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling
apoptosis, and VEGF-A levels were evaluated using confocal microscopy, plate reader-based assays, and ELISA techniques
biomarker of treatment response, supporting further validation in larger independent cohorts
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Fab fragment anti-VEGF-A; first intravitreal anti-VEGF for wet AMD. 대표 임상 효능: ORR 7.3% (ClinicalTrials.gov NCT00486018).
VEGF-A
Wet AMD, DME, RVO, myopic CNV
Global
Approved
bispecific antibodies like faricimab that simultaneously target VEGF a
viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory
Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1
targeting angiopoietin-like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling
apoptosis, and VEGF-A levels were evaluated using confocal microscopy, plate reader-based assays, and ELISA techniques
biomarker of treatment response, supporting further validation in larger independent cohorts
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.